4.6 Review

Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review

Journal

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 36, Issue 2, Pages 344-361

Publisher

WILEY
DOI: 10.1111/jgh.15330

Keywords

anti‐ TNF therapy; Crohn' s disease; endoscopic balloon dilatation; needle knife stricturotomy; stenosis; stricture

Funding

  1. National Health and Medical Research Council (NHMRC)
  2. GESA/Ferring IBD Clinician Establishment Award
  3. Australasian Gastro Intestinal Research Foundation (AGIRF)
  4. AbbVie
  5. Spotlight Foundation

Ask authors/readers for more resources

This study provides a summary of the latest advances in the treatment of stricturing Crohn's disease patients, indicating that anti-TNF drug therapy and endoscopic balloon dilation are effective strategies for avoiding surgery, while other drug therapies do not show significant benefits. Further evaluation is needed to assess the potential greater benefits of combining therapies.
Background and Aims Strictures are the commonest complication in Crohn's disease. Surgery and endoscopic dilation are the mainstays of treatment, while drug therapy has often been considered contraindicated. The benefit of nonsurgical treatments, particularly drug and endoscopic therapy, need to be defined. Methods Ovid MEDLINE, Embase, Emcare, PsycINFO, CINAHL and the Cochrane Library (inception until August 30, 2019) were searched. Studies with >= 10 patients with Crohn's disease strictures, reporting on outcomes following medication or endoscopic treatment, were included. Results Of 3480 records, 85 studies met inclusion criteria and formed the basis of this analysis. Twenty-five studies assessed drug therapy; none were randomized trials. Despite study heterogeneity anti-tumor necrosis factor (TNF) therapy appeared effective, with 50% of patients avoiding surgery after 4 years of follow up. No other drug therapy was of demonstrable benefit. Sixty studies assessed endoscopic therapy including 56 on endoscopic balloon dilation, two assessed needle knife stricturotomy, and two stent insertion. Dilation was equally effective for de novo and anastomotic strictures <= 5 cm in length, with most studies reporting a subsequent surgical rate of 30% to 50%. Repeat dilation was required in approximately half of all patients. Conclusions Anti-TNF drug therapy and endoscopic balloon dilation are effective strategies for avoiding surgery in patients with stricturing Crohn's disease. Additional endoscopic therapies require further evaluation. Early data suggest that combining these therapies may provide greater benefit than individual therapies. Optimization of current drug and endoscopic therapy, and the incorporation of newer therapies, are needed for stricturing Crohn's disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available